The Medical Letter on Drugs and Therapeutics
Dasiglucagon (Zegalogue) for Severe Hypoglycemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dasiglucagon (Zegalogue) for Severe Hypoglycemia
The FDA has approved dasiglucagon (Zegalogue – Zealand) for subcutaneous (SC) treatment of severe hypoglycemia in patients ≥6 years old with diabetes. Dasiglucagon is the third glucagon product to be marketed in the US that does not require...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dasiglucagon (Zegalogue) for Severe Hypoglycemia
Article code: 1631d
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.